In July, the Health Resources and Services Administration (HRSA) introduced a 340B Rebate Model Pilot Program that represents a meaningful evolution for the long-debated drug discount program. The 340B Drug Pricing Program has been under increasing scrutiny from drug manufacturers, consumer advocates, policymakers, and providers across the country. HRSA’s decision to launch a voluntary, tightly controlled rebate pilot provides a pragmatic way forward, one that balances the financial realities of manufacturers – who finance the program – with the access needs of safety-net providers. Far from a retreat, HRSA’s rebate model can strengthen 340B’s legitimacy, ensure program stability, and set the stage for sustainable reforms. 

The American Action Forum has written extensively on 340B, repeatedly suggesting that – although the result of a misaligned policy to address drug pricing in Medicaid – there are ample opportunities for reform that protect the integrity of the program and solve the distribution and accountability issues that have plagued 340B participants. 

As a brief reminder: The 340B Program, established in 1992, requires drug manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to eligible health care providers, known as “covered entities.” These entities include federally qualified health centers, children’s hospitals, rural hospitals, and other facilities that care for vulnerable patients. In turn, the savings from discounted drugs allow these providers to “stretch scarce resources,” expand services, and improve access to care. While straightforward in theory, this system has been fraught with disputes over distribution channels, contract pharmacy eligibility, and whether manufacturers can restrict access when drugs are not used in accordance with program guidelines. 

HRSA’s new rebate model pilot offers an alternative framework that attempts to address manufacturer concerns while reinforcing provider protections. The most immediate advantage of the rebate model is that it reduces litigation risk and helps bridge the divide between manufacturers and safety-net providers. Manufacturers have long argued that the upfront discount system exposes them to the risk of diversion and duplicate discounts, particularly in the era of widespread contract pharmacy use. Rebates provide a clearer transaction trail, minimizing disputes. 

The launch of the rebate pilot should also be seen in the context of broader health care financing reform. Federal policymakers are pursuing site-neutral payment reforms, Medicare Advantage oversight, and Medicare direct price negotiations. Within this landscape, 340B cannot remain static. By exploring a rebate model, HRSA signals that it is searching for ways to future-proof the program.  

To read more about the potential benefits of adopting the rebate model, as well as ideas for effectively implementing the new paradigm in various program participants, my recent comment letter submitted to HRSA in support of the rebate model can be found here.